Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer.
Animals
Antineoplastic Agents
/ administration & dosage
Breast Neoplasms
/ drug therapy
Carcinogenesis
/ drug effects
Cell Line, Tumor
/ transplantation
Drug Evaluation, Preclinical
Female
Fluorocarbons
/ administration & dosage
Gene Knockout Techniques
Humans
Integrin alphaVbeta3
Integrin beta3
Macrophages
/ drug effects
Mammary Neoplasms, Experimental
/ drug therapy
Mice
Nanoparticles
/ administration & dosage
Phagocytosis
Primary Cell Culture
Prodrugs
/ administration & dosage
Proto-Oncogene Proteins c-myc
/ antagonists & inhibitors
Tumor Microenvironment
/ drug effects
MYC
breast cancer
drug delivery
macrophages
nanoparticles
β3 integrin
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
02
2020
accepted:
30
05
2020
entrez:
21
7
2020
pubmed:
21
7
2020
medline:
4
5
2021
Statut:
epublish
Résumé
Tumor-associated macrophages (TAMs) enhance tumor growth in mice and are correlated with a worse prognosis for breast cancer patients. While early therapies sought to deplete all macrophages, current therapeutics aim to reprogram pro-tumor macrophages (M2) and preserve those necessary for anti-tumor immune responses (M1). Recent studies have shown that c-MYC (MYC) is induced in M2 macrophages
Identifiants
pubmed: 32685002
doi: 10.7150/thno.44523
pii: thnov10p7510
pmc: PMC7359087
doi:
Substances chimiques
Antineoplastic Agents
0
Fluorocarbons
0
Integrin alphaVbeta3
0
Integrin beta3
0
Myc protein, mouse
0
Prodrugs
0
Proto-Oncogene Proteins c-myc
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7510-7526Subventions
Organisme : NCRR NIH HHS
ID : S10 RR027552
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA216840
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA199092
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA091842
Pays : United States
Organisme : NIAMS NIH HHS
ID : T32 AR060719
Pays : United States
Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Expert Rev Anticancer Ther. 2004 Apr;4(2):289-302
pubmed: 15056059
Nano Lett. 2018 Jun 13;18(6):3571-3579
pubmed: 29722542
J Pharmacol Exp Ther. 2010 Dec;335(3):715-27
pubmed: 20801893
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830
ACS Nano. 2014 Jul 22;8(7):7305-17
pubmed: 24941020
Nanomedicine (Lond). 2015 Jan;10(2):241-51
pubmed: 25600969
J Exp Med. 2001 Mar 19;193(6):727-40
pubmed: 11257139
Biomedicines. 2017 Jun 21;5(2):
pubmed: 28635679
Blood. 2011 Oct 13;118(15):4199-208
pubmed: 21846901
J Cell Biol. 2010 Dec 13;191(6):1205-18
pubmed: 21135140
Transl Oncol. 2009 Dec;2(4):198-210
pubmed: 19956379
Chem Biol. 2006 Jul;13(7):745-51
pubmed: 16873022
Cancer Res. 2004 Dec 1;64(23):8604-12
pubmed: 15574767
Science. 2000 Mar 17;287(5460):1969-73
pubmed: 10720316
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Jpn J Cancer Res. 1998 Jul;89(7):775-82
pubmed: 9738985
J Leukoc Biol. 2002 Dec;72(6):1092-108
pubmed: 12488490
Eur Radiol Exp. 2020 Jan 3;4(1):2
pubmed: 31900689
Cell Growth Differ. 1990 Jul;1(7):339-43
pubmed: 2278885
PLoS One. 2015 Dec 23;10(12):e0145342
pubmed: 26699615
Immunol Rev. 2017 Mar;276(1):145-164
pubmed: 28258703
J Clin Invest. 1999 Jan;103(2):229-38
pubmed: 9916135
Circulation. 2004 Jul 6;110(1):84-90
pubmed: 15210600
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Theranostics. 2018 Nov 12;8(21):5842-5854
pubmed: 30613266
Mol Cancer Ther. 2015 Nov;14(11):2473-85
pubmed: 26269605
Adv Drug Deliv Rev. 2006 Dec 1;58(14):1471-504
pubmed: 17116343
Mol Cell Biol. 1990 Oct;10(10):5333-9
pubmed: 2204813
J Control Release. 2018 Feb 10;271:139-148
pubmed: 29277680
J Clin Invest. 2004 Jun;113(12):1684-91
pubmed: 15199403
FASEB J. 2007 Apr;21(4):1256-63
pubmed: 17215484
Nanomedicine. 2016 Jan;12(1):201-11
pubmed: 26515754
Nat Rev Cancer. 2002 Oct;2(10):740-9
pubmed: 12360277
J Biol Chem. 2001 Jun 1;276(22):19431-9
pubmed: 11278875
Proc Natl Acad Sci U S A. 2016 Feb 9;113(6):1564-9
pubmed: 26811453
Adv Mater. 2019 Apr;31(15):e1807211
pubmed: 30803083
Theranostics. 2018 Nov 29;8(22):6307-6321
pubmed: 30613299
Methods Mol Biol. 2016;1418:93-110
pubmed: 27008011
ACS Nano. 2019 Aug 27;13(8):8811-8825
pubmed: 31328922
PLoS One. 2012;7(9):e45399
pubmed: 23028984
Cancer Biother Radiopharm. 2003 Aug;18(4):627-41
pubmed: 14503959
Science. 2016 Apr 8;352(6282):227-31
pubmed: 26966191
Nature. 2007 May 3;447(7140):92-6
pubmed: 17450126
Cancer Res. 2016 Jun 15;76(12):3484-95
pubmed: 27216180
Adv Mater. 2019 Aug;31(35):e1902952
pubmed: 31267590
Pharmacol Rev. 2006 Mar;58(1):32-45
pubmed: 16507881
Nat Genet. 2002 Sep;32(1):107-8
pubmed: 12145662
Cancer Sci. 2014 Jan;105(1):1-8
pubmed: 24168081
FASEB J. 2008 Dec;22(12):4179-89
pubmed: 18697838
J Immunol Methods. 2000 Apr 21;238(1-2):29-43
pubmed: 10758233
Mol Cancer Ther. 2015 Jun;14(6):1286-1294
pubmed: 25824336
Oncogene. 2003 Sep 18;22(40):6151-9
pubmed: 13679853
Beilstein J Nanotechnol. 2014 Sep 24;5:1625-36
pubmed: 25383275
Nat Cell Biol. 2019 Sep;21(9):1113-1126
pubmed: 31451770
Nano Lett. 2008 Apr;8(4):1131-6
pubmed: 18302330
Circulation. 2002 Nov 26;106(22):2842-7
pubmed: 12451012
Biomaterials. 2008 Aug;29(23):3367-75
pubmed: 18485474
Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25
pubmed: 18509642
Cancer Lett. 2019 Oct 1;461:1-9
pubmed: 31288064
PLoS One. 2016 Apr 19;11(4):e0153550
pubmed: 27092773
Precis Nanomed. 2018 Jul;1(2):128-145
pubmed: 31249994
Theranostics. 2019 Oct 17;9(26):7981-8000
pubmed: 31754376
Nucleic Acids Res. 2009 Jan;37(1):1-13
pubmed: 19033363
Cancer Cell. 2019 Apr 15;35(4):588-602.e10
pubmed: 30930117
Nat Nanotechnol. 2016 Nov;11(11):986-994
pubmed: 27668795
Biomaterials. 2012 Nov;33(33):8632-40
pubmed: 22922023
Curr Cancer Drug Targets. 2003 Jun;3(3):163-75
pubmed: 12769686
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3830-5
pubmed: 11891322
Nat Commun. 2019 Sep 3;10(1):3974
pubmed: 31481662
Adv Exp Med Biol. 2017;995:141-153
pubmed: 28321816
J Am Chem Soc. 2019 Apr 17;141(15):6122-6126
pubmed: 30933483
Biomaterials. 2019 Dec;225:119515
pubmed: 31590119
Biosci Biotechnol Biochem. 1994 Jan;58(1):104-7
pubmed: 7764505
Int J Nanomedicine. 2008;3(3):311-21
pubmed: 18990940
Immunity. 2012 May 25;36(5):834-46
pubmed: 22503541
Cell. 1993 Jan 29;72(2):233-45
pubmed: 8425220
Nat Rev Cancer. 2011 Jun;11(6):411-25
pubmed: 21593787
ChemMedChem. 2014 Oct;9(10):2274-2285
pubmed: 24976143
Nano Lett. 2018 Nov 14;18(11):7330-7342
pubmed: 30339753
Nanotechnology. 2008 May 7;19(18):
pubmed: 21494419
Nat Biomed Eng. 2018 Aug;2(8):578-588
pubmed: 31015631
Sci Rep. 2015 Nov 18;5:16632
pubmed: 26577684
Blood. 2012 Jan 12;119(2):411-21
pubmed: 22067385
ACS Nano. 2020 Feb 25;14(2):1936-1950
pubmed: 31961656
J Gastroenterol Hepatol. 2001 Jan;16(1):22-8
pubmed: 11206311
Cell. 1989 Mar 10;56(5):777-83
pubmed: 2493990